Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2008-04-15
2008-04-15
Coleman, Brenda L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S218000, C514S221000, C514S222500, C514S222800, C514S254010, C514S255050, C514S266200, C514S269000, C514S272000, C514S274000, C514S362000, C514S385000, C514S386000, C514S389000, C514S392000, C514S422000, C540S460000, C540S470000, C540S473000, C540S492000, C540S504000, C540S505000, C540S506000, C540S508000, C540S509000, C540S514000, C540S545000, C540S569000, C540S571000, C540S575000, C544S008000, C544S011000, C544S283000, C544S285000, C544S286000, C544S287000, C544S292000, C544S298000, C544S301000, C544S
Reexamination Certificate
active
07358239
ABSTRACT:
The present invention concerns compounds of formula (I)a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -Z1-Z2- is a bivalent radical; R1, R2and R3are each independently selected from hydrogen, C1-6alkyl, hydroxy, halo and the like; or when R1and R2are on adjacent carbon atoms, R1and R2taken together may form a bivalent radical of formula; Alk is optionally substituted C1-6alkanediyl; the bivalent radicalis a substituted piperidinyl, an optionally substituted pyrrolidinyl, homopiperidinyl, piperazinyl or tropyl; R5is a radical of formulawherein n is 1 or 2; p1is 0, and p2is 1 or 2; or p1is 1 or 2, and p2is 0; X is oxygen, sulfur or ═NR9; Y is oxygen or sulfur; R7is hydrogen, C1-6alkyl, C3-6cycloalkyl, phenyl or phenylmethyl; R8is C1-6alkyl, C3-6cycloalkyl phenyl or phenylmethyl; R9is cyano, C1-6alkyl, C3-6cyclo-alkyl, C1-6alkyloxycarbonyl or aminocarbonyl; R10is hydrogen or C1-6alkyl; and Q is a bivalent radical. Processes for preparing said products, formulations comprising said products and their use as a medicine are disclosed, in particular for treating conditions which are related to impaired fundic relaxation.
REFERENCES:
patent: 3910930 (1975-10-01), Janssen et al.
patent: 3929801 (1975-12-01), Janssen et al.
patent: 4329348 (1982-05-01), Huebner
patent: 4470989 (1984-09-01), Henning et al.
patent: 4849335 (1989-07-01), Hofnung et al.
patent: 5137901 (1992-08-01), Junge et al.
patent: 5371094 (1994-12-01), Heine et al.
patent: 5492918 (1996-02-01), Wild et al.
patent: 5541199 (1996-07-01), Mewshaw
patent: 5696136 (1997-12-01), Heine et al.
patent: 6133277 (2000-10-01), Wigerinck et al.
patent: 2004/0019051 (2004-01-01), Van emelen et al.
patent: 28 52 945 (1980-06-01), None
patent: 0 048 218 (1981-09-01), None
patent: 0004358 (1982-01-01), None
patent: 0 068 261 (1983-01-01), None
patent: 0106749 (1988-12-01), None
patent: 2019838 (1979-11-01), None
patent: WO 93/17017 (1993-09-01), None
patent: WO 95/05383 (1995-02-01), None
patent: WO 97/28157 (1997-08-01), None
patent: WO 99/29687 (1999-06-01), None
patent: WO 00/75136 (2000-12-01), None
patent: WO 01/98306 (2001-12-01), None
T. Arakawa et al., New Aspects of Gastric Adaptive Relaxation, Reflex After Food Intake for More Food:Involvement of Capsaicin-senstivie Sensory Nerves and Nitric Oxide, 1997, J. Smooth Muscle Res. 33:81-88.
De Bruyn Marcel Frans Leopold
Van Emelen Kristof
Verschueren Wim Gaston
Wigerinck Piet Tom Bert Paul
Coleman Brenda L
Janssen Pharmaceutica N.V.
Woodcock & Washburn LLP
LandOfFree
Pyrrolidinyl, piperidinyl or homopiperidinyl substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidinyl, piperidinyl or homopiperidinyl substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidinyl, piperidinyl or homopiperidinyl substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2792939